Patents by Inventor Michel RECORD

Michel RECORD has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR REPROGRAMING IMMUNE ENVIRONMENT IN A SUBJECT IN NEED THEREOF
    Publication number: 20230138400
    Abstract: The present invention relates to methods and pharmaceutical compositions for reprograming immune environment in a subject in need thereof. The inventors demonstrated that DDA induces differentiation of tumor cells and stimulates the secretion and the production of modified exosomes with anti-tumor properties (DDA-exosomes) via a mechanism dependent of the expression of the LXRbeta in the parental cells. In particular, one object of the present invention relates to a method of promoting Th1 differentiation and functionality and CD8+ cytotoxicity in a subject in need thereof comprising administering to the subject a therapeutically effective amount of DDA or DDA-exosomes.
    Type: Application
    Filed: June 24, 2022
    Publication date: May 4, 2023
    Inventors: Sandrine SILVENTE POIROT, Marc POIROT, Julie LEIGNADIER, Philippe DE MEDINA, Michel RECORD
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR REPROGRAMING IMMUNE ENVIRONMENT IN A SUBJECT IN NEED THEREOF
    Publication number: 20200016177
    Abstract: The present invention relates to methods and pharmaceutical compositions for reprogramming immune environment in a subject in need thereof. The inventors demonstrated that DDA induces differentiation of tumor cells and stimulates the secretion and the production of modified exosomes with anti-tumor properties (DDA-exosomes) via a mechanism dependent of the expression of the LXRbeta in the parental cells. In particular, one object of the present invention relates to a method of promoting Th1 differentiation and functionality and CD8+ cytotoxicity in a subject in need thereof comprising administering to the subject a therapeutically effective amount of DDA or DDA-exosomes.
    Type: Application
    Filed: September 22, 2017
    Publication date: January 16, 2020
    Inventors: Sandrine SILVENTE POIROT, Marc POIROT, Julie LEIGNADIER, Philippe DE MEDINA, Michel RECORD